Publications by authors named "Michele Nanni"
Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks of toxicity, specifically immune-related adverse events (irAEs). There is a need for clear, effective guidelines for the management of irAEs during ICI treatment, motivating the Society for Immunotherapy of Cancer (SITC) to convene an expert panel to develop a clinical practice guideline.
View Article and Find Full Text PDFArticle Synopsis
- T-VEC is an intralesional treatment for advanced melanoma that has been studied alongside anti-PD-1 therapies in real-world scenarios.
- A review of T-VEC use from January 2017 to March 2018 included 83 melanoma patients, revealing three usage patterns: only T-VEC, T-VEC after anti-PD-1, and T-VEC concurrent with anti-PD-1.
- A quarter of patients stopped T-VEC due to the absence of injectable lesions, while 37% stopped due to disease progression, showing no significant differences based on the timing or presence of anti-PD-1 therapy.